Pricing Log in Create free account
Saturday 17 October 2026 Export AMRN’s income statement to Excel — free account

Amarin Corporation PLC

AMRN Healthcare Drug Manufacturers General

Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024. In the quarter to June 2026, revenue fell 42.0%, EPS grew 45.8% and free cash flow fell 60.2%, each against the same quarter a year earlier.

11.37 0.20 −1.73%
Market cap
$244.4M
P/E
0.0×
Fwd P/E
−398×
Dividend yield
—
F-score
7/9
Altman Z
−1.86
Beneish M
−3.26
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 244.36
Revenue 186.23
Net Income (27.12)
Free Cash Flow 15.57
Net Debt (314.85)
Current Ratio 3.67 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (398.00) (negative: loss-making)
P/S ratio 1.27
P/B ratio 0.53
Past 5Y EPS Growth —
This Y EPS Growth (565.48%) (below 0%: weak)
Next Y EPS Growth 42.55% (at or above 15%: strong)
Next Y revenue growth (16.97%) (below 0%: weak)
Next 5Y EPS Growth 12.64%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of 2.2×; over the ten years it ranged from −0.4× in 2025 to 30.1× in 2018.
P/S against its own 10 years 19.79%
10-year low 10-year high
P/B against its own 10 years 12.24%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 321 295 303 315
Receivables 134 122 127 93
Inventory 259 166 196 164
Other 12 13 24 31
725 595 650 603
2023 2024 2025 Q'26
Payables 53 40 45 19
ST’ Debt — — — —
Other — — — —
259 180 194 164

Compound Annual Growth %

10y 5y 3y
Sales 10.08% (19.04%) (16.67%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (6.05%) (8.29%)

Revenue $m

Mar Jun Sep Dec Year
’26 45 42 — — —
’25 42 73 50 49 214
’24 57 67 42 62 229
’23 86 80 66 75 307
’22 95 94 90 90 369
’21 142 154 142 144 583
’20 155 135 156 167 614
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 6 7 — — —
’25 (12) 17 (13) 15 7
’24 (13) (3) (2) (13) (31)
’23 (7) 7 7 (1) 7
’22 (99) (65) (18) 2 (180)
’21 (19) (15) (5) (28) (67)
’20 4 2 11 (38) (22)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 6 7 — — —
’25 (12) 17 (13) 15 7
’24 (13) (3) (2) (13) (31)
’23 (7) 7 7 (1) 7
’22 (99) (65) (18) 2 (180)
’21 (19) (15) (5) (28) (67)
’20 4 2 11 (38) (22)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.60) (0.37) — — —
’25 (0.76) (0.68) (0.37) (0.06) (1.87)
’24 (0.40) 0.07 (1.20) (2.40) (4.00)
’23 (0.80) (0.80) (1.00) (0.28) (3.00)
’22 (1.60) (3.60) (0.20) 0.00 (5.20)
’21 (0.08) 0.40 (0.60) 0.80 0.40
’20 (1.20) 0.20 (0.40) 0.20 (1.00)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 24.80 56.20 47.00 248.80 67.20 62.20 20.80 13.00 8.60 7.00

Analyst estimates 2026–2028

Powerpack
High 73.00 89.40 466.80 522.40 436.80 185.00 76.40 44.60 27.40 20.90
People
People Employees 215 241 530 965 1,000 560 365 275 275 80
Revenue/emp, $m 0.61 0.75 0.43 0.45 0.61 1.04 1.01 1.12 0.83 2.67
Income, $m
Income, $m Revenue 130 181 229 430 614 583 369 307 229 214
Gross margin, % 73.58 75.18 76.20 77.66 78.59 79.20 65.68 53.94 35.60 56.57
EBT (76) (55) (116) (22) (17) 11 (104) (54) (77) (36)
EBT margin, % (58.72) (30.27) (50.76) (5.23) (2.81) 1.94 (28.12) (17.49) (33.77) (16.87)
Net income (86) (68) (116) (23) (18) 8 (106) (59) (82) (39)
Depreciation 9 3 3 3 3 3 3 3 3 3
Per share, $
Per share, $ Revenue 12.28 13.38 15.42 25.09 32.17 29.45 18.41 15.06 11.13 10.30
Earnings (8.20) (5.00) (7.80) (1.40) (1.00) 0.40 (5.20) (3.00) (4.00) (1.87)
Cash flow (6.78) (2.43) (6.37) (0.55) (1.14) (3.36) (8.98) 0.34 (1.51) 0.32
Capex 0.00 0.00 0.00 (0.14) (0.01) 0.00 0.00 0.00 0.00 0.00
Free cash flow (6.78) (2.43) (6.38) (0.69) (1.15) (3.36) (8.98) 0.34 (1.51) 0.32
Book value (0.85) (4.81) 10.25 35.52 32.87 33.69 29.68 27.09 23.66 22.13
Shares, m 11 14 15 17 19 20 20 20 21 21
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 130.22 0.00 0.00 0.00 0.00
P/S 5.03 6.34 17.65 17.09 3.04 2.29 1.29 1.18 0.88 1.36
P/B 0.00 0.00 31.00 12.52 2.98 2.00 0.80 0.66 0.41 0.63
EV/Sales 5.17 6.60 16.91 15.72 2.25 1.53 0.50 0.20 (0.33) 0.02
EV/FCF (9.36) (36.41) (40.89) (570.08) (62.75) (13.45) (1.03) 8.75 2.41 0.78
Cash, $m
Cash, $m Operating cash flow (72) (33) (95) (9) (22) (67) (180) 7 (31) 7
Capex 0 0 0 (2) 0 0 (1) 0 — —
Free cash flow (72) (33) (95) (12) (22) (67) (180) 7 (31) 7
Balance, $m
Balance, $m Working capital 70 45 221 613 572 508 430 466 415 455
Total debt 116 123 80 59 10 11 20 — — —
Net debt 18 48 (170) (648) (505) (458) (310) (321) (295) (303)
Shareholders’ equity (9) (65) 152 608 628 667 595 552 486 459
Returns, %
Returns, % ROA (50.76) (41.31) (42.55) (3.57) (1.95) 0.76 (10.83) (6.88) (10.83) (5.72)
ROIC (480.23) 0.00 0.00 0.00 (10.02) 3.14 (23.18) (18.29) (29.94) (20.04)
ROE 93.18 110.45 (567.80) (6.32) (2.97) 1.19 (16.76) (10.30) (15.83) (8.21)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Amarin Corporation PLC vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SNY Sanofi $96.0B 21.3× — +17.35% (above 0%: growing) −90.76% (below 0%: shrinking) −45.06% (below 0%: shrinking) 75.47% 17.48% Compare
BIIB Biogen Inc. $34.8B 41.0× 31.5× +3.42% (above 0%: growing) −84.76% (below 0%: shrinking) +103.28% (above 0%: growing) 71.60% 5.52% Compare
OGN Organon & Co. $3.6B 17.4× 5.2× −2.26% (below 0%: shrinking) −26.79% (below 0%: shrinking) −82.97% (below 0%: shrinking) 54.36% 20.67% Compare
GRFS Grifols, S.A. $2.0B 8.5× — +5.76% (above 0%: growing) +466.92% (above 0%: growing) +300.52% (above 0%: growing) 36.47% 14.76% Compare
AMRN Amarin Corporation PLC $244.4M — (loss-making) — (loss-making) −41.97% (below 0%: shrinking) n/m −60.23% (below 0%: shrinking) 35.51% (28.45%)
NSRX Nasus Pharma Ltd. $37.1M — — — — −486.98% (below 0%: shrinking) — — Compare
MIRA MIRA Pharmaceuticals, Inc. $27.7M — (loss-making) — — n/m −50.76% (below 0%: shrinking) — 0.00% Compare
SCLX Scilex Holding Company $19.8M — (loss-making) — (loss-making) −22.78% (below 0%: shrinking) n/m −203.76% (below 0%: shrinking) 51.88% (385.02%) Compare
MDCX Medicus Pharma Ltd $6.3M — (loss-making) — — n/m −27.70% (below 0%: shrinking) — 0.00% Compare
Median of peers $993.5M 19.3× — +3.42% −55.77% −47.91% 54.36% 5.52%

All 21 Drug Manufacturers General stocks →

Amarin Corporation PLC (AMRN) key facts

  • Concern: Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024.
  • Amarin Corporation PLC (AMRN) is a Drug Manufacturers General company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, AMRN traded at $11.37, a market capitalization of $244.4 million.
  • Return on equity was −8.21% and debt-to-equity 0.00.
  • Its Piotroski F-score is 7 out of 9 and its Altman Z-score is −1.86 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Amarin Corporation PLC (AMRN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/AMRN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com